Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
Most popular shares in SMSFs
stocks
Will China strong arm BHP into lower iron ore prices?
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,264.30 | 8.50 | 0.09% |
CAC 40 | 7,918.00 | 123.36 | -1.53% |
DAX 40 | 24,241.46 | 369.79 | -1.50% |
Dow JONES (US) | 45,479.60 | 878.82 | -1.90% |
FTSE 100 | 9,427.47 | 81.93 | -0.86% |
HKSE | 26,290.32 | 462.27 | -1.73% |
NASDAQ | 22,204.43 | 820.20 | -3.56% |
Nikkei 225 | 48,088.80 | 491.64 | -1.01% |
NZX 50 Index | 13,467.26 | 103.60 | -0.76% |
S&P 500 | 6,552.51 | 182.60 | -2.71% |
S&P/ASX 200 | 8,958.30 | 9.20 | 0.10% |
SSE Composite Index | 3,897.03 | 36.94 | -0.94% |